Shares of Insmed INSM more than doubled in market value on Tuesday after reporting positive topline results from the phase III ASPEN study which evaluated its investigational oral drug brensocatib in ...
Source LinkShares of Insmed INSM more than doubled in market value on Tuesday after reporting positive topline results from the phase III ASPEN study which evaluated its investigational oral drug brensocatib in ...
Source Link
Comments